A B S T R A C T Three patients with idiopathic parkinsonism and six normal subjects were infused over a 4 hr period with 104.6 sc of dopamine-2'C (3,4-dihydroxyphenylethylamine, 3-hydroxytyramine) ,' the immediate precursor in the synthesis of the sympathetic neurohormone, noradrenaline (norepinephrine). Urine was collected during the infusion period, 0-2 hr, 2-4 hr, 4-8 hr, 8-24 hr, and thereafter for 4 additional days. Using a technique herein described, the various metabolic and biosynthetic products of dopamine, including noradrenaline and its metabolic products, were separated, identified, and their radioactivity measured.
dihydroxyphenylethylamine, 3-hydroxytyramine) was originally synthesized in 1910 by Mannich and Jacobsohn (1) . However, it was not until 1950 that this amine was found in mammalian tissue, at which time Goodall demonstrated its presence in the heart (2, 3) and in the adrenal gland along with L-DOPA (3,4-dihydroxyphenylalanine) (3, 4) . Since then dopamine has been demonstrated in multiple tissues (5) (6) (7) (8) (9) (10) (11) (12) , urine (13) (14) (15) (16) , and brain (17, 18) . In 1959, Bertler and Rosengren (19) , Sano et al. (20) , and later others (21) (22) (23) showed that dopamine existed in relatively high 1Dopamine-2-1'C HCI (3,4-dihydroxyphenylethylamine, 3 -hydroxytyramine), Nuclear-Chicago Corporation, Des Plaines, I11.
Received for publication 14 February 1969 and in revised form 25 July 1969. concentrations in the corpus striatum. However, it was Ehringer and Hornykiewicz (24) who first reported a decreased dopamine in the corpus striatum of patients with parkinsonism; subsequently, others confirmed this finding (25) (26) (27) . Barbeau ., Murphy, and Sourkes demonstrated a decreased urinary output of dopamine in parkinsonism (28) . More recently L-DOPA has been used in the treatment of parkinsonism with varied success (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) ; nevertheless, Cotzias et al. (37, 38) showed that with large daily doses (from 300 mg to 8 g) of L-DOPA a sustained improvement could be produced.
It is well established that L-DOPA and dopamine are precursors to noradrenaline, (norepinephrine) (3945).
Further, it has been shown that the sympathetic nerves and ganglia synthesize noradrenaline, but not adrenaline (42) ; noradrenaline is also found in the higher centers (46) (47) (48) (49) (50) including the basal ganglia (20) (21) (22) (23) (24) 26) . Recent evidence seems to indicate that dopamine is a neurohormone with transmitter functions in the central nervous system (22, 26, 27, (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) . In view of these findings and the fact that both dopamine and noradrenaline are decreased in the caudate, putamen, and substantia nigra in parkinsonism (24) The method for isolating and quantifying endogenous noradrenaline and the metabolic products of noradrenaline, as well as the metabolic products of dopamine, has been previously described (65, 66) . In brief, the basic metabolic products, separated on an Amberlite IRP-64s column, are adrenaline (epinephrine), metadrenaline (3-O-methyladrenaline, metanephrine), noradrenaline (norepinephrine), normetadrenaline (3-O-methylnoradrenaline, normetanephrine NM), dopamine, and 3-methoxytyramine (3-MT).
The acidic metabolic products, separated on a column of (76) . Fig. 1 cal elution pattern obtained in the separation of the acidic metabolic products. All acidic and basic metabolites were compiled and compared to those of normal subjects similarly infused with dopamine-2-'4C (Table I) .
RESULTS
The metabolic pattern of dopamine-2-14C in six normal subjects was compared to that of three patients with parkinsonism. Standard deviations were calculated on all metabolic products in the normal subjects but not in the parkinsonism patients since these patients very in degree from one another (Table I) .
From the results it appears that the most important change occurred in the formation of noradrenaline. There was a significant decrease in the radioactivity recovered as noradrenaline throughout the collection periods (Table I and Fig. 2) . As for the metabolic products of noradrenaline, there appeared to be a significant increase in DOMA during the infusion and early collection periods and a small but variable increase in NM conjugate (Table I ). There was no significant change in the other metabolic products of noradrenaline, i.e., MOMA, normetadrenaline, vanillic acid, and the conjugate of 3-methoxy-4-hydroxyphenylglycol (MHPG).
As for the metabolic products of dopamine-2-14C, there was a slight shift towards dopamine metabolism. This is reflected by an increase in the following metabolites of dopamine: DOPAC and the conjugates of HVA, DOPAC, 3-methoxy-4-hydroxyphenylethanol, and dopamine (Table I ). There were no significant changes in 3-methoxytyramine or its conjugate. HVA was normal in two patients and decreased in patient B. G. However, it should be noted that HVA takes its origin from DOPAC, and therefore, any decrease in HVA could be reflected by an increase in DOPAC, DOPAC conjugate, or HVA conjugate as was the case with patient B. G.
Peaks 11 and 12 showed significant decreases in all patients, but since these are unknown compounds, very little can be said about them except that they represent a small percentage of the total radioactivity recovered in each collection period. Preliminary evidence indicates that these unknowns are metabolic products of dopamine rather than noradrenaline. Approximately 75% of the infused dopamine was directly metabolized into dopamine-related metabolic products, i.e., 3-methoxytyramine, DOPAC, HVA, 3-methoxy-4-hydroxyphenylethanol (MHPE), 3,4-dihydroxyphenylethanol, and their respective conjugates, the conjugate of dopamine, and several unknowns (Table  I) . Of these metabolic products, HVA represents the largest single fraction (65) . The remaining 25% of the infused dopamine-2-14C was synthesized into noradrenaline and appeared in the urine as radioactive noradrenaline or the metabolic products of noradrenaline which are DOMA, NM, NOMA, vanillic acid, and their 4-0 sulfate conjugates, conjugates of 3-methoxy-4-hydroxyphenylglycol, and 3,4-dihydroxyphenylglycol (65, (67) (68) (69) . Other secondary metabolites of noradrenaline such as HVA, DOPAC, and their 4-0 sulfate conjugates are also present (70, 71) , but in these experiments their origin is principally from dopamine.
Whereas all the parkinsonism patients showed the same general metabolic pattern following an infusion of dopamine-2-1'C, they, as to be expected, varied in degree one from another (Table I and Fig. 2 ).
DISCUSSION
It is well established that noradrenaline is the neurohormone of the sympathetic nerves (42, 46, 72) . Furthermore, noradrenaline is present in various parts of the brain (46, 50) , including the corpus striatum (20) (21) (22) (23) (24) 26) , but especially great is its concentration in the hypothalamus (20, 21, 24, 26 FIGuRE 3 Biosynthetic pathway to the formation of noradrenaline (norepinephrine) and adrenaline (epinephrine).
noradrenaline is dopamine and that to dopamine is DOPA (42) (Fig. 3) . Recently, attention has been focused on dopamine as a neurohormone with transmitter functions in the central nervous system (22, 26, 27, (51) (52) (53) (54) (55) (56) (57) (58) (59) (60) (61) (62) (63) (64) (65) , and of special significance is the high concentration of dopamine in the nucleus caudate, putamen, pallidum, and substantia nigra (19) (20) (21) (22) (23) (24) (25) (26) (27) . Further, a decreased concentration of dopamine in the corpus striatum has been noted in parkinsonism (24) (25) (26) (27) . Whereas the introduction of dopamine might seem to be the logical approach to treating the depletion in idiopathic parkinsonism, nevertheless, this has not proven successful since the corpus striatum is considerably less permeable to circulating dopamine than it is to DOPA. In the corpus striatum the DOPA is readily decarboxylated to form dopamine. Therefore, efforts have been directed towards using the dopamine precursor, i.e. L-DOPA (4, 42) which in small amounts produced varied results (29) (30) (31) (32) (33) (34) (35) (36) (37) (38) but in large daily doses produced a sustained improvement (37, 38) .
The results of these experiments indicate that in patients with idiopathic parkinsonism there is a slight shift toward dopamine metabolism which is reflected by an increase in DOPAC and other dopamine metabolites (Table I ). The increase in DOPAC observed principally in the infusion period has also been noted in patients with neurogenic orthostatic hypotension (66) , but the meaning behind this increase remains unexplained. Nevertheless, this finding may be important since it could indicate a more local biochemical aberration of dopamine metabolism. Certainly the finding of decreased 3-methoxy-4-hydroxyphenylacetic acid (the principal metabolite of DOPAC) in the corpus striatum of parkinsonism patients (73) lends support to such a concept. Furthermore, since in parkinsonism the corpus striatum shows a deficit of dopamine (24) (25) (26) (27) , the immediate precursor to noradrenaline (42) , one would then expect to also find a decrease of noradrenaline in these same structures and this too has been demonstrated (26, 74) .
The question naturally arises as to whether or not the decrease in recovery of free radioactive noradrenaline in parkinsonism was related to debility, old age, or muscular inactivity. It is known that muscular exercise increases the release of noradrenaline (75) and this is reflected by an increase of noradrenaline in the urine. However, in these experiments the controls were maintained on bed rest during the infusion, for 24 hr postinfusion, and thereafter in a sedentary state. Also, similar dopamine-2-."C infusion experiments were performed on three normal male subjects (20-25 yr) maintained on bed rest and were then repeated after these subjects exercised moderately. In these rest-exercise experiments, there was no significant change of free radioactive noradrenaline. Further, since old age and debility could effect the noradrenaline synthesis, similar experiments were performed on an elderly (62 yr), debilitated, bed ridden individual but the results indicated that in this patient the noradrenaline synthesis was within normal limits.
Results herein described indicate that in idiopathic parkinsonism there is a decrease in the recovery of free radioactive noradrenaline in the urine following an infusion of the immediate precursor to noradrenaline, i.e., dopamine-2-"C (Table I and Fig. 2) . The pathogenesis of this diminished recovery of radioactive noradrenaline, renal function being normal, could be the result of an increase in noradrenaline metabolism or a decrease in its synthesis. Increased metabolism of noradrenaline is seen in the human during such stressful situations as severe thermal injury (76); however, in severe burns there is not only a decrease in the urinary recovery of radioactive noradrenaline but also a concomitant increase in noradrenaline metabolic products and a marked increase in the utilization rate of the infused dopamine-2-14C (76) . In contrast, the opposite situation is seen in neurogenic hypotension where there is a decrease synthesis of noradrenaline with a concomitant decrease in noradrenaline metabolic products (66) ; and further, hypotension, a salient feature of neurogenic orthostatic hypotension, is sufficiently common to parkinsonism to have warranted speculation of a possible relationship between these two syndromes (77) (78) (79) . Therefore, this similarity with neurogenic hypotension and the decreased recovery of radioactive noradrenaline in idiopathic parkinsonism would seem to imply that in parkinsonism there is also an alteration in noradrenaline synthesis with a sympathetic nervous system involvement. However, the answer is considerably more complex than this indicates since in idiopathic parkinsonism there is also a decrease of dopamine in the corpus striatum (24) (25) (26) (27) and the urine (28) and a decrease of HVA in the corpus striatum (73) . This would clearly indicate that the decreased recovery of radioactive noradrenaline observed in these experiments could be secondary to a defect further back than dopamine in the synthesis of noradrenaline, i.e., in the conversion of DOPA to dopamine (DOPA is rapidly decarboxylated to dopamine) or tyrosine to DOPA or possibly phenylalanine to tyrosine.
